Abstract: The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising the nucleic acid molecules. The present disclosure also provides compositions comprising the recombinant polypeptides and methods of making and using the recombinant polypeptides.
Type:
Grant
Filed:
December 29, 2017
Date of Patent:
February 16, 2021
Assignees:
BioGend Therapeutics Co., Ltd., Osteopharma Inc.
Abstract: The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising the nucleic acid molecules. The present disclosure also provides compositions comprising the recombinant polypeptides and methods of making and using the recombinant polypeptides.
Type:
Application
Filed:
December 29, 2017
Publication date:
November 7, 2019
Applicants:
BioGend Therapeutics Co., Ltd., Osteopharma Inc.
Abstract: The invention pertains to polypeptide variants with increased heparin-binding ability. Increased heparin-binding ability is achieved by addition, insertion, and/or substitution of an amino acid sequence X1X2X3X4X5X6 (SEQ ID NO. 1 or NO.2). Polypeptide variants according to the invention are particularly suited for stimulation of chondrogenesis, osteogenesis, and wound healing. The invention also pertains to amino acid molecules that encode said polypeptide variants, host cells containing said nucleic acid molecules, and processes for producing the polypeptide variants.